Investigational drug · Phase 3
BFF
Also called: BFF MDI 320, BFF MDI 160
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Asthma.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
0 still active
All registered trials
14
Any phase or sponsor naming "BFF"
First trial start
2020
Dec 15, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BFF", any sponsor or status.
- Phase 312
Conditions studied
As listed on its trial records.
- Asthma
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "BFF" as an intervention, largest first.
- Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)Pivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT02465567 · 8,588 participants · Start Jun 30, 2015 · Primary completion Jul 26, 2019
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI 14.4/9.6 μg and 2 more · For: COPD
Sites: Andalusia, Alabama; Athens, Alabama; Birmingham, Alabama · 741 sites in all
- Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPDPivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT02766608 · 2,389 participants · Start May 31, 2016 · Primary completion Dec 1, 2017
Drug: BFF MDI 320/9.6 μg; BFF MDI 160/9.6 μg and 3 more · For: Chronic Obstructive Pulmonary Disorder
Sites: Athens, Alabama; Birmingham, Alabama; Dothan, Alabama · 259 sites in all
- Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT04609878 · 2,274 participants · Start Dec 15, 2020 · Primary completion Mar 21, 2025
Drug: BGF MDI 320/28.8/9.6 μg; BGF MDI 320/14.4/9.6 μg and 2 more · For: Asthma
Sites: Saraland, Alabama; Phoenix, Arizona; Sun City West, Arizona · 360 sites in all
- Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT04609904 · 2,187 participants · Start Mar 1, 2021 · Primary completion Mar 20, 2025
Drug: BGF MDI 320/28.8/9.6 μg; BGF MDI 320/14.4/9.6 μg and 2 more · For: Asthma
Sites: Chandler, Arizona; Tempe, Arizona; Tucson, Arizona · 317 sites in all
- A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)Pivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT02497001 · 1,902 participants · Start Aug 10, 2015 · Primary completion Jan 5, 2018
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI (PT003) 14.4/9.6 μg and 2 more · For: COPD
Sites: Andalusia, Alabama; Jasper, Alabama; Peoria, Arizona · 190 sites in all
- A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)Pivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT02727660 · 1,876 participants · Start Apr 29, 2016 · Primary completion Apr 4, 2018
Drug: BFF MDI (PT009) 320/9.6 μg; BFF MDI (PT009) 160/9.6 μg and 1 more · For: Chronic Obstructive Pulmonary Disorder
Sites: Dothan, Alabama; Huntsville, Alabama; Sheffield, Alabama · 282 sites in all
- A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT05202262 · 645 participants · Start Jan 12, 2022 · Primary completion Feb 26, 2025
Drug: BFF MDI 320/9.6 μg; BFF MDI 160/9.6 μg and 2 more · For: Asthma
Sites: Chandler, Arizona; Tucson, Arizona; Bakersfield, California · 142 sites in all
- Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT02536508 · 627 participants · Start Aug 10, 2015 · Primary completion Sep 12, 2017
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI 14.4/9.6 μg and 1 more · For: COPD
Sites: Dothan, Alabama; Jasper, Alabama; Peoria, Arizona · 64 sites in all
- Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®Pivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT03262012 · 416 participants · Start Aug 9, 2016 · Primary completion Jun 15, 2018
Drug: BGF MDI (PT010); GFF MDI (PT003) and 2 more · For: COPD
Sites: Bunkyō City, Japan; Chūōku, Japan; Date-gun, Japan · 79 sites in all
- A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT05755906 · 374 participants · Start Feb 27, 2023 · Primary completion Nov 19, 2024
Drug: BFF MDI 160/9.6 μg BID (320/19.2μg/day); BD MDI 160 μg BID (320 μg/day) · For: Asthma
Sites: Chandler, Arizona; Mesa, Arizona; Tucson, Arizona · 104 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Chemical Profiling by UHPLC-MS/MS and In Vitro Antioxidant, Antimicrobial, and Cytotoxic Properties of Lepidoceras peruvianum Kuijt Leaves and Fruits.
Jara MRA, Bautista KG, Pérez FIO, et al. · Rapid Commun Mass Spectrom 2026
- BFF-piRNA-seq reveals conserved processing hotspots in flies and mice.
Haase A, Hafner M, Konstantinidou P, et al. · Res Sq 2026
- Cell-free filtrate from algicidal bacteria drives concentration-dependent damage and recovery in Karenia mikimotoi: Insights into harmful bloom persistence.
Gu J, Chen Q, Xiao H, et al. · Mar Pollut Bull 2026
- The Beaver Futures Framework: Stakeholder value perspectives on future human-beaver coexistence.
van Zelst B, Arts K, Dekker I, et al. · Ambio 2026
- Budesonide/formoterol fumarate dihydrate versus budesonide with a novel suspension technology for uncontrolled asthma: phase 3 LITHOS study.
Papi A, Wise RA, Jackson DJ, et al. · ERJ Open Res 2026
- Budesonide/formoterol fumarate dihydrate versus budesonide with a novel suspension technology for uncontrolled asthma: phase 3 VATHOS study.
Jackson DJ, Wise RA, Papi A, et al. · ERJ Open Res 2026
Also in development for Asthma
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.